Related Experiment Videos
[Effect of a new synthetic anticholinergic (oxytropium bromide) on acetylcholine-induced bronchospasm]
Abstract:
Oxytropium bromide, a new synthetic anticholinergic agent, delivered by a dose inhaler, was compared to a placebo in a cross-over double-blind trial. The drop in FEV1 after administration of increasing doses of acetylcholine aerosol spray was measured 45 min after administration of the test drug, and the dose-response curve was determined. The placebo modified neither acetylcholine threshold dose (bronchial sensitivity) nor the slope of the curve (bronchial reactivity). Oxytropium bromide elevated the response threshold and decreased bronchial reactivity to vagal stimuli.
Insights
Oxytropium bromide, an anticholinergic agent, was found to reduce bronchial reactivity and increase the threshold for acetylcholine-induced bronchoconstriction in a clinical trial. This suggests potential benefits for managing airway hyperresponsiveness.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Trials
Background:
- Anticholinergic agents are used in respiratory diseases.
- Vagal nerve stimulation plays a role in bronchoconstriction.
- Assessing bronchial reactivity is crucial for understanding airway function.
Purpose of the Study:
- To evaluate the efficacy of oxytropium bromide in modulating airway responses.
- To compare oxytropium bromide to a placebo in a controlled setting.
- To determine the effects of oxytropium bromide on bronchial sensitivity and reactivity.
Main Methods:
- A cross-over, double-blind, placebo-controlled trial was conducted.
- Participants received either oxytropium bromide or placebo via a dose inhaler.
- Bronchial reactivity was assessed by measuring FEV1 changes after acetylcholine aerosol challenge.
Main Results:
- Placebo did not alter acetylcholine threshold dose or bronchial reactivity.
- Oxytropium bromide significantly elevated the acetylcholine response threshold.
- Oxytropium bromide demonstrated a significant decrease in bronchial reactivity to vagal stimuli.
Conclusions:
- Oxytropium bromide effectively reduces vagally mediated bronchoconstriction.
- The drug shows potential in managing conditions characterized by airway hyperresponsiveness.
- Oxytropium bromide offers a therapeutic option for modulating airway reactivity.